- Investors should distinguish confirmed information from expectations, proposals and early-stage indicators.
- Investors should distinguish confirmed information from expectations, proposals and early-stage indicators.
- Hemogenyx Pharmaceuticals PLC is in focus following a company update published or highlighted on 19 October 2026.
Faron announced that complete survival data for 25 patients in the melanoma cohort of MATINS will be presented at the October 2026 oncology congress. The patients had metastatic melanoma that had progressed despite checkpoint-inhibitor treatment, making the population clinically challenging and heavily pretreated.
Nuformix reported further positive target-engagement results from its pilot inhaled study of NXP002, a drug-repurposing programme being developed for idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and related interstitial lung diseases. The company said testing showed statistically significant modulation of TGF-β/SMAD signalling, a pathway involved …
PureTech Health announced that Phase 1b results for LYT-200, developed by its founded entity Gallop Oncology, have been accepted for an oral presentation at the October 2026 oncology congress. The data concern relapsed or refractory high-risk myelodysplastic syndromes and acute myeloid leukaemia, patient groups …
GSK plc (LSE:GSK) is one of the FTSE 100 stocks in focus on Monday, 19 October 2026, after the drugmaker presented the first global data for its experimental lung cancer treatment risvutatug rezetecan, known as Ris-Rez. Shares were marginally higher at about 1,863p in …
Haleon PLC (LSE:HLN) is in focus on Monday, 19 October 2026, as investors look for steady earners amid a volatile market. The consumer health group behind Sensodyne, Panadol, Advil and Centrum traded around 375p after a period in which healthcare and consumer staples shares …
Smith & Nephew plc (LSE:SN.) is in focus on Monday, 19 October 2026, as the medical technology group trades close to its lowest levels of the year. The maker of orthopaedic implants, sports medicine products and advanced wound care treatments has struggled with slower …
The latest move adds to an extraordinary turnaround. In July, Oxford Nanopore shares plunged around 11% to 106.5p after the company warned that revenue for the six months to 30 June would come in at about £116.5 million, below market expectations, mainly because of …